![Figure 1. T-PLL involving lymph node, peripheral blood, pleural fluid, and bone marrow. Diffuse infiltrate of T-PLL in the cervical lymph node by morphology (A [original magnification ×400, hematoxylin and eosin stain]) and CD8 immunostain (B [original magnification ×400]). T-PLL in the peripheral blood (C [original magnification ×1000, Wright-Giemsa stain]) and pleural fluid (D [original magnification ×1000, Wright-Giemsa stain]). Persistent and diffuse involvement of bone marrow by T-PLL status post–4-week treatment with alemtuzumab by morphology (E [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (F [original magnification ×40]). Addition of JAK inhibitor tofacitinib to alemtuzumab markedly decreased the leukemic cells in a repeat bone marrow biopsy by morphology (G [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (H [original magnification ×40]).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/1/27/10.1182_bloodadvances.2017010470/3/advances010470f1.jpeg?Expires=1724240721&Signature=H5vEYhmedAtSuZet4oXXjOmilyH~uqzLYvrwsVM97-TvDDY6GA5vEzmWzChnQvZsAeX6wADuwTRWXrgmGQZMTWEh4OaJdNRuqCUP9Ztlc4ukugGU65xSbrZH090FCRe3Czv2qMzXr1kmC24iTw0GqMp1FG6fG6nwePQCkdYU2rg1TTwqKCBSONtPY-kRkbyo7aLA68V070xyZAMTbaIAftu1Ph1SeTj7rvapaes5lvNFi7rN7fbM5mFiGufryBzrGPrzCrm0xoCiK6e3H60pC9a6P0Uc3XrfSAbluuQkO9UwPh6ymMFHRMaaKWeCU5~5doJ71gq1wy5YEEcL884D9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
T-PLL involving lymph node, peripheral blood, pleural fluid, and bone marrow. Diffuse infiltrate of T-PLL in the cervical lymph node by morphology (A [original magnification ×400, hematoxylin and eosin stain]) and CD8 immunostain (B [original magnification ×400]). T-PLL in the peripheral blood (C [original magnification ×1000, Wright-Giemsa stain]) and pleural fluid (D [original magnification ×1000, Wright-Giemsa stain]). Persistent and diffuse involvement of bone marrow by T-PLL status post–4-week treatment with alemtuzumab by morphology (E [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (F [original magnification ×40]). Addition of JAK inhibitor tofacitinib to alemtuzumab markedly decreased the leukemic cells in a repeat bone marrow biopsy by morphology (G [original magnification ×40, hematoxylin and eosin stain]) and CD8 immunostain (H [original magnification ×40]).
